Oragenics Inc. (NYSE: OGEN) Featured in Virtual Coverage of the Summer Investor Summit 2020
Oragenics (NYSE: OGEN) is focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. The company has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allow Oragenics to accelerate the development of much-needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat and esophagus. For more information, visit the company's website at www.oragenics.com To view IBN’s virtual coverage of the Summer Investor Summit, visit http://IBN.fm/InvestorSummitSummer2020 About…







